David was CEO of NightstaRx and led the company through a successful NASDAQ listing and M&A transaction. He was previously Vice President of Johnson & Johnson’s Vision Care Franchise and Regional President at Allergan plc. David is Chairman of Oxular and is a Board member of the Glaucoma Foundation.
Director and CEO
Thomas is co-founder, CEO and a Board member of Oxular. He is an experienced and successful entrepreneur who has helped to build four previous private-equity-backed ventures. He was formerly co-founder and CEO of Aciex Therapeutics, where he brought its lead program to NDA and led the company through a successful M&A exit.
Ronald is co-founder, Chief Scientific Officer and a Board observer of Oxular. He brings more than 30 years of medical device and drug product development experience. Ronald has developed novel ophthalmic microcatheters for surgical treatment of glaucoma and retinal disease, sub-retinal access devices, diagnostic microspheres, and drug-releasing implants. He was previously a co-founder and Chief Scientific Officer of iScience Interventional.
Dr. Rafiq Hasan
Rafiq is the CEO of EXACT Therapeutics, a clinical-stage Anglo-Norwegian biotech company. An MD by training, Rafiq has 25 years in the pharma industry globally. As Senior Vice President and Global Head of Ophthalmology at Bayer, he grew the business of Eylea® from launch to over $2.5bn in five years, including its launch in five indications in three years.
Dr. Dmitrij Hristodorov
Dmitrij Hristodorov is a Principal at Forbion. Prior to this, he was Senior Director of Global Business Development & Licensing at Bayer Pharma, where he was mainly responsible for ophthalmology, cardiology, nephrology, and pulmonology. His spectrum of activities included scouting, evaluation, negotiation, and transaction for in- and out-licensing. Previously, Dmitrij spent two years in R&D as Head of Pharmacology Lab in Ophthalmology. His activities included target discovery and preclinical development. Dmitrij received his PhD in Immunology (summa cum laude) from the University of Aachen/Fraunhofer IME, Germany, in 2013.
Dina is a partner with NeoMed Management and Advisor to Omega Funds. Dina has been investing in the private equity and venture capital healthcare industry in Europe and the U.S. since 2001. Previously at 3i plc in London and Index Ventures in Geneva, Dina’s successful investments include Endosense, EUSA Pharma, Novexel and Wilson Therapeutics.
Dina serves on the Board of Directors of Imago BioSciences, Oxular and Spruce Biosciences and is a member of the Venture Capital Platform Council of Invest Europe. Dina is a CFA charterholder and holds a Ph.D. degree in molecular and cellular biology from Paris VI University, France and carried out postdoctoral research at Brown University and at the Fox Chase Cancer Centre in Philadelphia.
Christina is co-founder and Managing Director of V-Bio Ventures. With more than 20 years of investment experience in European venture capital, Christina was previously a partner with Forbion Capital Partners (formerly ABN AMRO Capital) where she led and managed a series of successful biotech investments since 2001. Christina has a scientific background, holding a PhD in Developmental Biology from the University of Cologne, Germany, and an MSc in Biology from the University of Darmstadt, Germany.
Tassos is an investment manager at IP Group and specializes in early stage investing in the life science sector. Before joining IP Group, Tassos was a business development executive at CRUK Commercial Partnerships (formerly CRT) where he led the intellectual property sourcing, licensing, and spin-out creation of CRUK-funded technologies. He has experience in technology transfer both in the US and the UK, and has also held an investment analyst role with SR One, GSK’s venture capital arm. Tassos earned a PhD in Molecular Oncology at the University of Oxford and a postdoc at the University of Chicago.
Geert-Jan Mulder, MD
Geert-Jan is Managing Partner at Forbion and has a leading role in the Investment Team and the Portfolio. He is an experienced life sciences investor who led the firm’s successful investments and served on the Boards (sometimes also in an executive capacity) of portfolio companies: bluebird bio, (IPO on Nasdaq 2013), Acorda (IPO on Nasdaq 2006), PanGenetics (sold to Abbott in 2009), Transave (reverse-merger into Insmed in 2010), Exosome Diagnostics (sold to Bio-Techne), Promedior (sold to Roche in 2020), and KaNDy Therapeutics (sold to Bayer in 2020). Geert-Jan serves on the Board of several Forbion portfolio companies. In addition to his portfolio management activities, he works closely with management teams of various Forbion portfolio companies on clinical development strategies and regulatory matters, such as IND/ NDA filings, Special Protocol Approval (SPA), and US/EU Orphan designations for several products reflected by being a co-author of several Forbion and Forbion portfolio-related scientific publications.